AstraZeneca, Lilly to develop and commercialize BACE inhibitor to treat Alzheimer’s disease
The AZD3293 is an oral beta secretase cleaving enzyme (BACE) inhibitor, which significantly reduced amyloid beta levels in the cerebro-spinal fluid of Alzheimer’s patients and healthy volunteers in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.